Novartis PPA litigation
This article was originally published in The Tan Sheet
Executive Summary
California jury clears Novartis of charges that the firm concealed material facts about the presence of phenylpropanolamine (PPA) in cough/cold products, firm announces Jan. 23. The jury also rejects allegations that Triaminicin and Tavist D "were unsafe products with inadequate warnings," Novartis says. Firm notes a New Jersey jury cleared the firm of similar charges in a case one week earlier. California, New Jersey verdicts are first in a number of cases filed against consumer health product manufacturers concerning the use of PPA in cough/cold products. PPA was voluntarily removed from the market in November 2000 at the request of FDA (1"The Tan Sheet" Nov. 13, 2000, p. 4)...
You may also be interested in...
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.